Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.

Novartis, a pharmaceuticals company, and the National Football League have announced an unprecedented partnership that names Novartis as the official first-in-category corporate pharmaceutical partner ...

Recent health news highlights include Apollo Hospitals' investment in AI for staff workload management, controversies ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

The exclusive negotiating window for Visa, a 30-year NFL sponsor, to renew its deal with the league has expired, and the NFL ...

A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...

Tricuspid regurgitation (TR) is common in patients with atrial functional mitral regurgitation (AFMR) but its impact is not ...

Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...